NovaBridge Biosciences
NASDAQ:NBPBiotechnology
Healthcare
$0.90 -4.78%
-$0.07 today
- Market cap
- $104.10M
- Beta
- 1.48
- P/E (TTM)
- -25.5
- EPS (TTM)
- -$0.40
52W Low $1.46High $6.79
Volume 0.87M
Average 0.90M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$20.60M
FY 2025 · Annual
Investing Cash Flow
$104.97M
FY 2025 · Annual
Financing Cash Flow
$57.73M
FY 2025 · Annual
Cash Flow Statement
Mixed currencies
Metric | FY2021 Dec 2021 · CNY | FY2022 Dec 2022 · CNY | FY2023 Dec 2023 · CNY | FY2024 Dec 2024 · CNY | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (2.33B) | (2.51B) | (208.18M) | (362.72M) | (88.34M) |
| Depreciation & Amortization | 34.14M | 63.82M | 1.06M | 7.14M | 856K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 608.61M | 357.15M | 10.26M | (14.23M) | 5.97M |
| Change in Working Capital | 394.52M | 552.06M | (37.2M) | (20.52M) | 17.07M |
| Accounts Receivables | 97.42M | 33.08M | 0 | 0 | 0 |
| Inventory | (27.24M) | 27.24M | 0 | 0 | 0 |
| Accounts Payables | 107.85M | 0 | 0 | 0 | 0 |
| Other Working Capital | 216.49M | 491.75M | (37.2M) | (20.52M) | 17.07M |
| Other Non-Cash Items | 321.18M | 431.48M | 161.2M | 5.9M | 43.84M |
| Operating Cash Flow | (973.09M) | (1.1B) | (72.85M) | (384.42M) | (20.6M) |
| Capital Expenditures | (29.93M) | (45.83M) | (164.35K) | (350.34K) | (7K) |
| Acquisitions (Net) | (6M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (10.17B) | (7.41B) | 0 | (1.79B) | (49.96M) |
| Sales of Investments | 9.48B | 7.91B | 0 | 801.66M | 154.89M |
| Other Investing Activities | 0 | 26K | (107.47M) | 452.53K | 47K |
| Investing Cash Flow | (727.21M) | 458.38M | (107.63M) | (992.42M) | 104.97M |
| Debt Repayment | 0 | 2.75M | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 61.91M |
| Common Stock Repurchased | 0 | (3.08M) | (8.66M) | (2.45M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 593.92M | 60.86M | 407.88K | 0 | (4.19M) |
| Financing Cash Flow | 593.92M | 42.36M | (8.25M) | (2.44M) | 57.73M |
| Effect of Forex Changes | (128.77M) | 389.2M | 36.89M | (327.04M) | 276K |
| Net Change in Cash | (1.24B) | (212.86M) | (151.58M) | (1.71B) | 142.37M |
| Free Cash Flow | (1B) | (1.15B) | (73.02M) | (384.77M) | (20.6M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$88.3M
+ D&A$856.0K
+ Stock-Based Comp$6.0M
+ Deferred Tax$0
+ Working Capital$17.1M
+ Other Non-Cash$43.8M
= Operating Cash Flow-$20.6M
- Capex-$7.0K
= Free Cash Flow-$20.6M
Analysis
FY2025 free cash flow is -$20.6M. FCF conversion is 23.3% of net income. Operating cash flow was -$20.6M, with capex of -$7.0K. The largest bridge item is Other Non-Cash at $43.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 5, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 2, 2026 | |
| 6-K | 6-K filing | Oct 28, 2026 | |
| 6-K | 6-K filing | Oct 26, 2026 | |
| 6-K | 6-K filing | Oct 23, 2026 |
Does NBP generate free cash flow?
NovaBridge Biosciences (NBP) generated -$20.60M of free cash flow in fiscal 2025.
How much operating cash flow does NBP produce?
Operating cash flow was -$20.60M, before capital expenditures of $7,000.00.
Continue the stock analysis
Jump to another research area for this company.